SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Biopharma Conference being held in Miami, FL, on March 11-13, 2024.

圣地亚哥，2024年3月4日（环球通讯社）--Belite Bio，Inc.（纳斯达克：BLTE），一家临床阶段的生物制药药物开发公司，专注于推进针对退行性视网膜疾病的新型治疗方法，这些疾病的医疗需求尚未得到满足，今天宣布，高管团队将参加2024年3月11日至13日在佛罗里达州迈阿密举行的Leerink Partners全球生物制药会议。

The Company will host a fireside chat on Wednesday, March 13, 2024, at 10:00 am ET. A webcast of the fireside chat can be accessed under the 'Events' tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.

该公司将于2024年3月13日（星期三）上午10:00（美国东部时间）举办一次炉边聊天。可以在贝利特生物网站投资者关系部分的“事件”选项卡下访问炉边聊天的网络广播，网址为：https://investors.belitebio.com/presentations-events/events.回放将在演示日期后的90天内存档。

About Belite Bio Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases.

关于Belite Bio Belite Bio是一家临床阶段的生物制药药物开发公司，专注于推进针对退行性视网膜疾病的新型治疗方法，这些疾病具有显着未满足的医疗需求，例如Stargardt疾病1型（STGD1）和晚期干性年龄相关性黄斑变性（AMD）中的地理萎缩（GA），以及特定的代谢疾病。

Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

贝利特的主要候选人Tinlarebant是一种旨在减少眼睛中毒素积累的口服疗法，目前正在青少年STGD1受试者的3期研究（DRAGON）和GA受试者的3期研究（PHOENIX）中进行评估。有关更多信息，请在推特、Instagram、LinkedIn、脸书上关注我们，或访问www.belitebio.com。

Media and Investor Relations Contact:Jennifer Wuir@belitebio.com Julie Fallonbelite@argotpartners.com .

媒体和投资者关系联系人：JenniferWuir@belitebio.com朱莉Fallonbelite@argotpartners.com。